Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic
Prokop Vodička, Andrea Janíková, Kamila Polgárová, Juraj Ďuraš et autres
0 citationsBlood Advances
David Belada
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
355Publications signalées
8450Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchCNS Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders
Publications récentes
POSTER: IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Lorenzo Falchi, Marcel Nijland, Kim Linton, Neta Goldschmidt et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: ABCL-489: Primary Outcomes From the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)
Jason Westin, Georg Lenz, Marek Trnený, John M Burke et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ABCL-489: Primary Outcomes From the Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (frontMIND)
Jason Westin, Georg Lenz, Marek Trnený, John M Burke et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Lorenzo Falchi, Marcel Nijland, Kim Linton, Neta Goldschmidt et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-489: Primary Outcomes From the Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (frontMIND)
Jason Westin, Georg Lenz, Marek Trnený, John M Burke et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
Umberto Vitolo, Juan Miguel Bergua Burgués, Johannes Duell, Michal Kwiatek et autres
0 citationsThe Lancet Haematology
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma
David Belada, Faithlore P. Gardner, Ana C. de Oliveira, Juan‐Manuel Sancho et autres
1 citationHemaSphere
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEPA) in newly diagnosed CD30-positive peripheral T-cell lymphomas with integrated ctDNA analysis: Results of the phase 2 CHEPA trial.
Marek Trněný, Pavel Klener, Jozef Michalka, David Belada et autres
0 citationsJournal of Clinical Oncology
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Eva Domingo-Domenech, Barbara Pro, Tim Illidge, Steven Horwitz et autres
0 citationsBlood Cancer Journal
Guidelines for the management of adverse events following CD19 CAR-T cell therapy in adult patients with lymphomas and acute lymphoblastic leukaemia – consensus of expert panel from certified centres in Czechia and Slovakia for 2025
František Folber, Flóra Benkő, Barbora Čemusová, J. Vydra et autres
0 citationsTransfuze a hematologie dnes
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
Lorenzo Falchi, Marcel Nijland, Huiqiang Huang, Kim Linton et autres
25 citationsThe Lancet
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.